ArticleACS omega2025
Influence of Solvent Choice on Mitomycin C Loading and Stability in Electrospun Polyvinylidene Fluoride Nanofibers.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the influence of solvent systems on incorporating the hydrophilic drug mitomycin C (MMC) into electrospun polyvinylidene fluoride (PVDF) nanofibers, with a focus on the often-overlooked issue of active substance degradation during storage. MMC was dissolved in either water or acetone and added to the electrospinning solution, followed by quantification of drug loading using liquid chromatography. Dissolution of MMC in water resulted in poor drug loading efficiency. In contrast, acetone led to significantly higher incorporation, with 50.66% loading for PVDF containing 0.01% MMC and 26.63% for PVDF with 0.1% MMC. However, storage at 4 °C over 21 days resulted in a substantial decline in MMC content, indicating challenges in long-term stability. In vitro testing using mouse fibroblasts revealed no cytotoxic effects of the nanofibrous layers and demonstrated a reduction in fibroblast proliferation in MMC-loaded samples compared to pure PVDF controls. These findings highlight the importance of solvent selection for effective drug incorporation and point to the potential of PVDF-based nanofibers for antifibrotic applications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.